about
Melanoma-restricted genesPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsPeritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugsDrug conjugation to hyaluronan widens therapeutic indications for ovarian cancerA BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150.Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccinationCirculating miR-182 is a biomarker of colorectal adenocarcinoma progression.Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis.Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST).L-arginine metabolism in myeloid cells controls T-lymphocyte functions.A gene expression signature associated with survival in metastatic melanomaDifferential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer.Human miRNome profiling in colorectal cancer and liver metastasis development.Reconstruction of gene regulatory modules from RNA silencing of IFN-α modulators: experimental set-up and inference methodAutologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastasesA human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.Role of arginine metabolism in immunity and immunopathology.Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies.Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4.Myeloid-derived suppressor cell heterogeneity and subset definition.Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase.Role of microRNAs in HTLV-1 infection and transformation.Immunotherapy for EBV-associated malignancies.The microRNA regulatory network in normal- and HTLV-1-transformed T cells.Predictors of immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma: a case report.T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.Reverse immunoediting: When immunity is edited by antigen.Functional avidity-driven activation-induced cell death shapes CTL immunodominance.Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters.A circulating miRNA assay as a first-line test for prostate cancer screeningEffective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase.
P50
Q24793788-DDDAAC9C-32A4-4CA6-B315-946908B5CDE4Q27339832-E89EB0FE-D836-4D8B-932F-38E16BFD0D16Q28544821-0B10E2EE-EC48-4A96-910D-C75B25290C4FQ28648402-B292C7AB-5F5E-4E2B-9A1C-1CFE1110082EQ33632095-EC71C072-C70B-4F83-96B8-88505CBEF616Q33671654-B5A09567-B861-4609-96B0-D15F39E807B0Q33892137-A64DD5EA-BA51-4E1D-8F6E-4E96A9AEC4FBQ33932627-E42D0CCF-ED9A-4CFE-8D58-5CFA53CA84D8Q34334326-914F8E65-D734-432D-8C12-BB88F65C45EDQ34976152-A6B40FCA-5DFD-4CEC-9456-400A0899F516Q35058504-AA1A38DC-EFA1-46B0-8D84-B03606DC70D4Q35155944-81CEC310-2ECD-4F25-B36F-41EBD443EA86Q35220047-CDEE45BA-FE60-4982-8FE9-9068868EFAA1Q35402927-8CFB67ED-4E10-47C6-AD72-8FE2E5A0A505Q35814028-B0A3F8BF-C845-48B8-A947-783E62F5009EQ35954854-86CD6058-2576-4367-A120-08587576762FQ36004284-58CDF637-805D-4273-9039-B422C6B2A525Q36568998-4787BF6A-84E4-40D8-BA28-0651A4C2D3A0Q36617600-BC665AF9-F7A5-4A53-B342-5CB122492B36Q37006834-E166ECB4-067A-4A68-BB0F-56DDE77DFDDCQ37034571-E97353CC-9308-4847-9F0A-38AE3375DEAEQ37118160-8D6BADB5-108E-4BF2-B9F0-80D55DF91D89Q37224604-E6B01A5F-5F6D-4963-A6B7-1C1177DCFB7BQ37354906-575F9DD8-AEB9-419B-8035-9D6F4D1EDDFDQ37695457-5DA3349C-F260-44AB-8197-0F8B0062B9A0Q37713530-F2C6988A-BC02-48E4-9BE2-2715CB268484Q37769847-8CFC71C0-F353-41EA-B925-3F1E2A77F8B8Q37845178-FAB40B14-F7B1-4D3E-87AC-96CAE6392496Q37994929-C311FCC3-618A-47AF-B602-8E0F0D8E6096Q38258034-D10F2788-77EF-4C8D-9E29-4CA15F8E60B4Q38746598-FE8B7672-6A00-4EDC-8F81-4598AEC87B85Q38821761-1FFF4F6E-B0C0-4E8A-83C7-4AAE9904D9C9Q38954082-0B1372EA-D945-4AEC-89E9-F7D4DEEA92E0Q39383951-2D958583-2E79-4B00-A462-9B405C353E2FQ39547351-B8FF3495-75DB-47FF-BEF4-6952AA6279D8Q39725373-25381C83-BF2D-4CB3-BB11-097210A7A5B8Q39776441-1BE4657B-61AD-4424-8372-9CDA2205A33BQ40327296-903117FC-C0C0-4A55-B11E-3523FB6EA473Q40377436-ABFDB456-B72B-48CD-8050-668DB3945ED4Q40609370-DF9436EF-496B-4288-9474-FC1A595393AF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paola Zanovello
@ast
Paola Zanovello
@en
Paola Zanovello
@es
Paola Zanovello
@nl
Paola Zanovello
@sl
type
label
Paola Zanovello
@ast
Paola Zanovello
@en
Paola Zanovello
@es
Paola Zanovello
@nl
Paola Zanovello
@sl
prefLabel
Paola Zanovello
@ast
Paola Zanovello
@en
Paola Zanovello
@es
Paola Zanovello
@nl
Paola Zanovello
@sl
P106
P1153
7004827725
P21
P31
P496
0000-0002-9996-2669